Sortilin, carbamylation, and cardiovascular calcification in chronic kidney disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35190032.
- Also identified by DOI 10.1016/j.kint.2021.11.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sortilin appears to play important roles in the pathogenesis of vascular and metabolic diseases, such as cardiovascular calcification. Post-translational modifications of sortilin (i.e., phosphorylation or carbamylation) are among the key mechanisms of its actions. Recent data extended the role of carbamylated sortilin to the pathogenesis of cardiovascular calcifications in chronic kidney disease. Whether therapeutic tools potentially available to inhibit the carbamylation process in chronic kidney disease patients would allow preventing cardiovascular calcifications remains to be demonstrated.
Medical subject headings
- Protein Carbamylation
- Renal Insufficiency, Chronic